Skip to main navigation Skip to search Skip to main content

Guidelines of guidelines: focal therapy for prostate cancer, is it time for consensus?

  • Sean Ong*
  • , Kenneth Chen
  • , Jeremy Grummet
  • , John Yaxley
  • , Matthijs J. Scheltema
  • , Phillip Stricker
  • , Kae Jack Tay
  • , Nathan Lawrentschuk
  • *Corresponding author for this work
  • Epworth HealthCare
  • University of Melbourne
  • Peter Maccallum Cancer Centre
  • Singapore General Hospital
  • Monash University
  • University of Queensland
  • UnitingCare Health
  • Department of Surgery, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
  • St Vincent's Prostate Cancer Centre, Sydney, Australia
  • St. Vincent's Hospital Sydney
  • Garvan Institute of Medical Research
  • Royal Melbourne Hospital

Research output: Contribution to journalReview articleAcademicpeer-review

25 Downloads (Pure)

Abstract

Objective: To provide a summary and discussion of international guidelines, position statements and consensus statements in relation to focal therapy (FT) for prostate cancer (PCa). Methods: The European Association of Urology-European Association of Nuclear Medicine-European Society for Radiotherapy and Oncology-European Society of Urogential Radiology-International Society of Urological Pathology-International Society of Geriatric Oncology and American Urological Association-American Society for Radiation Oncology-Society of Urologic Oncology guidelines were interrogated for recommendations for FT. PubMed and Ovid Medline were searched for consensus statements. Only studies in English since 2015 were included. Reference lists of the included articles were also interrogated and a manual search for studies was also performed. Results: Our results showed a lack of long-term randomised data for FT. International Urological guidelines emphasised the need for more high-quality clinical trials with robust oncological and toxicity outcomes. Consensus and positions statements were heterogenous. Conclusion: A globally accepted guideline for FT planning, technique and follow-up are still yet to be determined. Well-designed studies with long-term follow-up and robust clinical and toxicity endpoints are needed to improve our understanding of FT and create uniform guidelines to streamline management and follow-up.
Original languageEnglish
Pages (from-to)20-31
Number of pages12
JournalBJU international
Volume131
Issue number1
Early online date2022
DOIs
Publication statusPublished - Jan 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • consensus
  • focal therapy
  • guidelines
  • prostate cancer
  • prostate carcinoma

Fingerprint

Dive into the research topics of 'Guidelines of guidelines: focal therapy for prostate cancer, is it time for consensus?'. Together they form a unique fingerprint.

Cite this